Data supporting manuscript "Cell-free, high-density lipoprotein-specific phospholipid efflux assay predicts incident cardiovascular disease."

A high-density lipoprotein function assay predicts cardiovascular disease risk
Levels of HDL-cholesterol and total cholesterol are typically used to calculate the risk of coronary artery disease (CAD), but these measures are imperfect. Assessing HDL function in removing excess lipids that accumulate in arterial lesions may be a better way to predict CAD, but current approaches to measure this function require specialized techniques and sample preparation and cannot be applied in a routine clinical setting. IMasaki Sato, Edward Neufeld and colleagues developed an assay to measure HDL-specific phospholipid efflux based on the binding of endogenous plasma apoA-I and other exchangeable apolipoproteins to artificial lipid-donor particles. In three clinical cohorts, this assay detected associations between efflux function and CAD even after adjustment for other measures of HDL,and could be used to predict coronary artery plaque burden. This assay is amenable to automation and thus could be applied as a routine diagnostic test.

高密度脂蛋白功能检测可预测心血管疾病风险
临床中通常通过高密度脂蛋白胆固醇（HDL-cholesterol）与总胆固醇水平计算冠状动脉粥样硬化性心脏病（coronary artery disease, CAD）的发病风险，但此类检测指标存在一定局限性。评估高密度脂蛋白（HDL）清除动脉粥样硬化病灶中蓄积过量脂质的功能，或为预测冠心病的更优方案，但当前检测该功能的技术需依赖专用实验设备与标准化样本前处理流程，无法应用于常规临床诊疗场景。
佐藤正树（Masaki Sato）、爱德华·诺伊菲尔德（Edward Neufeld）及其研究团队开发了一种检测方法：基于内源性血浆载脂蛋白A-I（apoA-I）与其他可交换载脂蛋白结合人工脂质供体颗粒的原理，量化高密度脂蛋白特异性磷脂外流能力。在三项临床队列研究中，即便在校正其他高密度脂蛋白相关指标后，该检测方法仍能检出磷脂外流功能与冠状动脉疾病之间的显著关联，且可用于预测冠状动脉斑块负荷。该检测方法适配自动化操作流程，因此可作为常规诊断检测项目推广应用。